TL;DR
- 1.Oral peptides achieve under 1% systemic bioavailability. Even Rybelsus, with Novo Nordisk's full engineering behind it, reaches only 0.4 to 1% of the injected equivalent.
- 2.Injectable peptides deliver 75 to 100% bioavailability by bypassing all three digestive barriers that destroy oral peptides before they reach your blood.
- 3.BPC-157 genuinely survives stomach acid for over 24 hours in lab conditions. Whether it reaches your bloodstream from the gut is still an open research question with no human pharmacokinetic data.
- 4.Topical GHK-Cu delivers only 0.006% to the viable epidermis layer. It still works because the target tissue is the skin surface, not deep dermis.
- 5.Subcutaneous and intramuscular injections both deliver near-complete bioavailability. The difference is timing: IM peaks faster, subcutaneous gives a steadier release curve.
Oral semaglutide, the drug that launched a thousand copycat compounds, achieves 0.4 to 1% bioavailability. Novo Nordisk spent years and billions of dollars engineering it to survive the human stomach. They solved the problem partially using a synthetic absorption enhancer called SNAC, patented the formulation, and still ended up with 99% of every dose destroyed before it reaches your blood. That is the state of the art for oral peptides in 2026.
Oral bioavailability of semaglutide (Rybelsus), the most technically advanced oral peptide on the market. Subcutaneous semaglutide (Ozempic) achieves roughly 89%. Same molecule, different route: a roughly 100-fold difference. Source: Batista et al., Pharmaceutics, 2025.
For the research peptides most people are actually running (BPC-157, ipamorelin, GHK-Cu, TB-500), the situation is more complicated than "oral bad, injectable good." Each route has a specific mechanism, a specific ceiling, and a specific use case. The route you pick determines how much of what you paid for actually reaches your tissues. This article gives you the numbers on all three.
Why Do 99% of Oral Peptides Never Reach Your Blood?
Three sequential barriers destroy nearly every peptide you swallow. Not one. Three. Any peptide that survives the first two still faces a third. Getting through all three at meaningful concentration is the problem no oral formulator has fully solved, even with pharmaceutical-grade engineering.
Your stomach runs at pH 1 to 2, optimized for the enzyme pepsin. Pepsin cleaves peptide bonds at aromatic amino acids: phenylalanine, tyrosine, tryptophan. Most therapeutic peptides contain at least one of these residues. Exposure time in an average stomach is 30 to 120 minutes. That is long enough to fragment most peptides into non-functional pieces before they reach the small intestine.
If a peptide survives the stomach, it enters the small intestine where four more enzymes wait: trypsin, chymotrypsin, elastase, and carboxypeptidase. These target different peptide bonds than pepsin, so a fragment that pepsin missed is usually caught here. Brush-border membrane enzymes at the intestinal surface then attack anything that reaches the epithelial layer.
Peptides above roughly 1 kDa face near-zero passive diffusion across the intestinal epithelium. The gut wall evolved to absorb amino acids and small di-peptides, not intact therapeutic peptides of 10 to 50 amino acids. Anything that slips through the epithelial cells enters the portal vein and goes to the liver first, where a second round of degradation runs before the compound reaches systemic circulation.
A 2025 review in Pharmaceutics by Batista et al. covering all clinically approved oral peptides found bioavailability below 1% in every case tested. Insulin is destroyed within one hour under intestinal conditions. Desmopressin reaches 0.1%. Octreotide, even with a chemical absorption enhancer added, achieves only 0.7%. These are the best cases in the approved literature.
Think of your digestive system as a nightclub with three bouncers at three different doors. The first bouncer (stomach acid) checks your chemical structure. The second bouncer (intestinal enzymes) rechecks anyone who got past the first. The third bouncer (gut wall and liver) blocks everything too large or too recognizable as a foreign protein. A peptide drug has to fool all three to get inside. Most do not make it past the first door.
BPC-157 Is the Exception. Here Is What That Actually Means.
BPC-157 (body protection compound-157) is a 15-amino-acid peptide originally isolated from human gastric juice. That origin matters: it was literally found in stomach acid, which means it was under evolutionary pressure to survive that environment. In laboratory conditions, BPC-157 resists pepsin degradation for more than 24 hours. That is genuinely anomalous. Most therapeutic peptides fragment within minutes under the same conditions.
This makes oral BPC-157 plausible for local effects on the GI tract. A 2025 review in Inflammopharmacology by Sikiric et al., covering 36 published studies from 1993 to 2025, documented cytoprotective and pro-healing effects throughout the gut wall after oral administration in animal models. For gut-targeted goals (mucosal repair, IBD, leaky gut), the oral route may deliver the peptide directly to the tissue it is meant to repair without requiring it to reach systemic circulation first.
"BPC-157 is unusual among gastrointestinal peptides in its stability under acidic and enzymatic conditions, providing a theoretical basis for oral activity that most synthetic therapeutic peptides cannot claim. Systemic bioavailability data from oral administration in humans remains an open research question."
Sikiric et al., Inflammopharmacology, 2025
The critical distinction: surviving the stomach is not the same as reaching your bloodstream. No published human pharmacokinetic study has measured systemic BPC-157 concentration after oral dosing. Animal models confirm gut-healing effects from oral administration. Whether oral BPC-157 reaches systemic circulation at therapeutic levels for tendon repair or systemic anti-inflammatory goals is not answered in the indexed literature. If your goal is gut healing, oral may be the right route. If your goal is tendon or ligament repair, the evidence supports injection. See the full breakdown of who responds to BPC-157 and who does not. The complete mechanism and dosing data is on the BPC-157 peptide page.
Injectable Delivers 75 to 100%: What Changes Between Subcutaneous and IM?
Injectable peptides bypass all three GI barriers completely. Neither your stomach, your intestinal enzymes, nor your liver process the compound before it enters systemic circulation. Subcutaneous and intramuscular injections both achieve 75 to 100% bioavailability for most peptides. The difference between them is not how much gets in. It is how fast and how consistently it arrives.
| Factor | Subcutaneous | Intramuscular |
|---|---|---|
| Bioavailability | 75-100% | 75-100% |
| Time to peak (Tmax) | Slower (minutes to hours) | Faster (30-60 min typical) |
| Release profile | Sustained, stable plasma levels | Higher initial peak, faster fall |
| Best for | GH secretagogues, repair peptides, daily protocols | Acute protocols, faster-acting compounds |
| Needle | 27-31 gauge, half-inch | 22-25 gauge, 1 to 1.5 inch |
For GH secretagogues like ipamorelin and CJC-1295, subcutaneous is the preferred route. The goal is to mimic the body's natural pulsatile GH release pattern, which means a slow, predictable absorption curve matters more than a high fast peak. For more on the injection errors that undermine that timing, the peptide dosing guide covers the most common protocol mistakes.
IM injection delivers compound into highly vascularized muscle tissue. Blood flow in muscle is higher than in subcutaneous fat, producing faster peak concentrations. For insulin, IM peaks at roughly 60 minutes versus 90 minutes subcutaneously. For most research peptides, the kinetic difference matters clinically only when you need a fast local or systemic effect. Tissue repair protocols generally benefit more from the sustained subcutaneous release profile.
Subcutaneous semaglutide (Ozempic) bioavailability versus 0.4-1% for oral semaglutide (Rybelsus). Same drug, same dose range, different route: roughly a 100-fold difference in how much reaches your blood. A 2025 meta-analysis (Bhatt et al., PMC12085783) found oral semaglutide also carried a 79% higher rate of treatment discontinuation due to GI side effects compared to injectable.
Do Topical Peptides Actually Penetrate Skin? The 0.006% Number Explained.
Here is the number that makes people question whether topical GHK-Cu does anything at all: a flow-through diffusion cell study by Hostynek et al. found that across isolated viable epidermis, just 0.006% of the applied GHK-Cu dose reached the receptor phase below. Across full split-thickness skin, 2% passed through. Across just the stratum corneum (the outermost dead-cell layer), 20% penetrated.
GHK-Cu dose reaching viable epidermis as a percentage of topical application, from the Hostynek et al. diffusion cell study. The peptide concentrates heavily in the stratum corneum itself at 438-fold the applied concentration, which is where its primary biological activity occurs.
Those numbers are not a failure. They describe where GHK-Cu is supposed to work. The 438-fold concentration increase in the stratum corneum means the peptide deposits into the outermost skin layer in very high amounts. Collagen synthesis support, wrinkle reduction, and wound-healing effects are all documented at the skin surface and upper epidermis. The biologically relevant target tissue for topical GHK-Cu is not deep dermis. It is the surface layer where the peptide is actually concentrating.
Palmitoylation helps penetration: adding a fatty acid chain (Pal-GHK) improved permeation to 4.61% through synthetic epidermis versus 3.86% for plain GHK-Cu in Franz diffusion cell testing. Lipid modification makes the compound more compatible with the lipid-rich stratum corneum. Most commercial GHK-Cu serums use the palmitoyl form for this reason.
Clinical evidence confirms local activity: a 12-week randomized controlled trial on 41 women found GHK-Cu cream significantly reduced periocular wrinkle volume and increased skin density versus placebo, consistent with stratum-corneum-level activity. For a detailed look at realistic GHK-Cu timelines and what the before-and-after data actually shows, see the GHK-Cu before and after breakdown.
When Topicals Do Not Work
Topical peptides work when the target tissue is the skin. They do not work for systemic goals. A topically applied BPC-157 will not heal your tendon. GHK-Cu serum will not raise systemic copper peptide levels at any measurable concentration. The stratum corneum barrier that limits drug delivery is the same feature that protects you from absorbing everything your skin contacts. That is a feature, not a bug.
Your skin genetics do affect penetration at the margins. FLG (filaggrin) gene variants that reduce barrier protein expression leave the stratum corneum structurally thinner and more permeable. People with eczema or ichthyosis-related FLG mutations absorb topical compounds more readily and experience more irritation from concentrated formulations. For most people, the 0.006% viable-epidermis penetration number applies. For FLG variant carriers, penetration is likely somewhat higher, though no topical peptide-specific data for this genotype is published yet.
How the FDA Got Oral Peptides to Work (And What Engineering It Required)
Three oral peptide drugs now hold FDA approval. Each required a different engineering approach to get past the three digestive barriers. None of them ended up with injectable-level bioavailability.
| Drug | Peptide | Approved | Technology | Bioavailability |
|---|---|---|---|---|
| Rybelsus | Semaglutide (GLP-1) | 2019 (T2D), 2025 (CV) | SNAC absorption enhancer | 0.4 to 1% |
| Mycapssa | Octreotide | 2020 | Sodium caprylate | 0.7% |
| Icotyde | Icotrokinra (IL-23 antagonist) | March 2026 | Cyclic peptide structure | Not published |
The SNAC approach used in Rybelsus is instructive. SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) creates a high-pH microenvironment in the stomach that temporarily suppresses pepsin activity and fluidizes the epithelial membrane in a narrow local zone around the tablet. The drug has approximately 30 minutes to be absorbed through that window before stomach mixing disperses the SNAC. This is why Rybelsus must be taken on an empty stomach with no more than four ounces of water, 30 minutes before anything else. Disrupt that microenvironment and bioavailability drops further still.
The result after all that engineering: 0.4 to 1%. A 2025 meta-analysis by Bhatt et al. (PMC12085783) found that at equivalent doses, subcutaneous semaglutide reduced HbA1c significantly more than oral (SMD 0.21, 95% CI 0.04 to 0.38). Oral semaglutide also carried a 79% higher risk of treatment discontinuation due to GI side effects (relative risk 1.79, 95% CI 1.13 to 2.83). The engineering solved the bioavailability problem partially. It did not solve the tolerability problem that comes from escalating doses to compensate for low absorption.
Icotyde (icotrokinra), approved by FDA in March 2026 for plaque psoriasis, takes a structurally different approach: a cyclic peptide backbone that is inherently more resistant to proteolytic enzymes than linear peptides. J&J described it as the first targeted oral peptide in its drug class. The cyclic structure limits the enzyme's ability to find and cleave the vulnerable bond. This design-level solution is more elegant than the absorption-enhancer approach, and it represents where oral peptide technology is heading. Whether similar cyclic peptide design reaches research-grade compounds in the next decade is an open question.
How to Match Your Delivery Route to Your Goal
The question is not which route is objectively best. It is which route fits what you are trying to accomplish. Here is the practical decision tree the existing content almost never lays out clearly.
Choose oral if your primary goal is gut lining repair, mucosal healing, or GI inflammation. BPC-157's acid stability makes oral a plausible route for GI-targeted effects. For any other peptide with a systemic goal, the bioavailability data does not support oral as your primary route. You are delivering under 1% at best.
The right choice for BPC-157 tendon repair, GH secretagogues (ipamorelin, CJC-1295), Epithalon, MOTS-c, and any peptide where you need sustained systemic levels. Subcutaneous gives stable plasma levels, easy administration, and near-complete bioavailability. Most research peptide protocols default here for good reason.
GHK-Cu, palmitoylated cosmetic peptides, and copper peptide serums work at the skin surface layer. If your goal is collagen support, wrinkle reduction, or wound healing at skin level, topical is the right and sufficient route. Do not expect systemic anti-aging effects from topical application of any current peptide formulation.
Your genetics shift the equation slightly at the margins. FLG filaggrin variants that reduce skin barrier thickness may increase topical peptide absorption somewhat. If you want to understand how your CYP enzyme variants affect the other compounds in your stack (even though peptides themselves largely bypass hepatic CYP pathways), the CYP3A4 metabolizer guide shows exactly which compounds in a typical protocol run through liver enzymes and which ones do not.
The genetic angle for delivery routes is still an emerging area of research. No published clinical study has linked a specific SNP to meaningfully different peptide absorption across routes. The bioavailability data applies to essentially everyone, with the FLG skin-barrier exception being the most plausible but least-studied variation. For a full picture of how your specific genotype shapes your peptide protocol from selection through dosing, the PeptidesDNA report covers the variants that matter.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Can you take BPC-157 orally?
BPC-157 is one of the only research peptides that genuinely survives stomach acid for over 24 hours in lab conditions. This makes oral administration plausible for gut-local effects like mucosal healing and gut lining repair. However, no published human study has measured systemic BPC-157 levels after oral dosing, so for tendon repair or systemic anti-inflammatory effects, injection remains the evidence-supported route.
Does oral BPC-157 work for tendon healing?
The published animal model evidence for BPC-157 tendon healing comes primarily from injection protocols, not oral administration. BPC-157 survives stomach acid unusually well for a peptide, but there is no human pharmacokinetic data showing it reaches systemic circulation at therapeutic concentrations after oral dosing. If tendon or ligament repair is your goal, subcutaneous injection is the route with documented evidence behind it.
Do topical peptides like GHK-Cu actually work?
Yes, for skin-layer targets. GHK-Cu penetrates into the stratum corneum at 438-fold concentration above the applied dose, and a 12-week randomized controlled trial confirmed significant wrinkle reduction and skin density improvement versus placebo. Only 0.006% of the applied dose reaches viable epidermis below the surface layer. Topical GHK-Cu works where it concentrates: at the skin surface. It will not produce systemic anti-aging effects from topical application alone.
Why does oral semaglutide work if peptides have less than 1% bioavailability?
Rybelsus works because the dose is calibrated for 0.4 to 1% bioavailability. You take 7 to 14 mg orally to achieve plasma levels equivalent to a much smaller injected dose. The drug uses SNAC, a patented absorption enhancer that temporarily suppresses stomach enzymes and opens the epithelial membrane for a short absorption window. Even so, subcutaneous semaglutide outperforms oral on HbA1c reduction, and a 2025 meta-analysis found oral semaglutide carries a 79% higher discontinuation rate due to GI side effects.
Does subcutaneous or intramuscular injection work better for peptides?
Both routes achieve 75 to 100% bioavailability for most peptides, so neither is superior on that metric. Subcutaneous injection gives slower, more sustained plasma levels, which suits protocols that want steady exposure like GH secretagogues and BPC-157 for tissue repair. Intramuscular injection produces faster peak concentrations, which suits acute applications where speed matters. Most research peptide protocols default to subcutaneous because the sustained release profile fits most goals better.
Can intranasal peptide delivery work as an alternative to injection?
Intranasal delivery bypasses first-pass liver metabolism and can achieve meaningful bioavailability for small peptides via the nasal mucosa. Selank and Semax are commonly administered intranasally in Russian clinical protocols, and the pharmacokinetics support this route for those specific compounds. BPC-157 intranasal use exists in practice but has no published human pharmacokinetic data for this route. The nasal mucosa is more permeable than gut epithelium but offers a smaller absorption surface area, which limits total dose delivery per administration.
How does my genetics affect which delivery route works best for me?
For injectable peptides, your genetics have minimal impact on delivery since you bypass all digestive barriers entirely. For topical peptides, FLG (filaggrin) gene variants that reduce skin barrier thickness may increase absorption slightly. For oral peptides, P-glycoprotein (ABCB1) variants that reduce gut efflux transporter activity may modestly improve the small amount that gets through. These genetic differences are real but small compared to the roughly 100-fold bioavailability gap between oral and injectable routes.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.